Research Programmes

Quicklinks
	Opportunity to join the HTA programme's Commissioning Boards
	Health Services and Delivery Research programme
	NIHR Clinical Trials Unit support funding
	Calls for proposals - all NETSCC programmes
	NETSCC is part of NIHR www.nihr.ac.uk
	Remit advice
Latest News
	NIHR funds research projects to tackle obesity in children and adults
	Call for UK Clinical Research Collaboration Clinical Trials Unit Registration
	New study into fluid in the middle ear funded
	New NETS Annual Review
	Detecting fetal abnormalities in pregnancy
	NETSCC News Feeds Follow NIHR on Twitter

you are here › Home › Funding Opportunities › Which programme

Cancer Research

The NIHR HTA Programme (www.hta.ac.uk) and Cancer Research UK (www.cancerresearchuk.org) are both funders of late phase clinical trials and other well-designed studies in the NHS.

Would my cancer research idea be of interest to Cancer Research UK or the HTA programme?

This page sets out some information to guide applicants for research grants so that they can decide which organisation to apply to in the first instance. In line with the requirements of both organisations , parallel applications will not be accepted. The following table lists some of the priorities for studies funded by the two programmes, however, you are strongly advised to go to the relevant web-sites for further information on these and other funding schemes and, if still uncertain, to contact either organisation directly. The two organisations are happy to offer advice, based on the submission of an abstract informally, prior to an application for funding.

	CRUK	NIHR HTA
Board or Workstream	Clinical Trials Awards and Advisory Committee (CTAAC)	HTA Clinical Evaluation and Trials
Research Question	Primarily efficacy (including OS, PFS, DFS and RR) Clinical and cost-effectiveness.	HTA studies usually assess costeffectiveness of the intervention in the NHS.
Study design	Mainly phase III/IV randomised controlled trials and phase II/feasibility studies	Pragmatic phase III or IV RCTs, or other suitable designs including diagnostic accuracy studies and evidence synthesis.
Intervention	Cancer treatment directed at the tumour such as chemotherapy, radiotherapy and surgery with the principle objective of improving survival.	Other interventions including diagnostic tests, screening, tests and programmes, other interventions to improve quality of life and mortality.
Outcomes	Disease progression, survival and mortality. Trial associated short and long-term toxicity, including late effects and QoL. Bio-medical evaluation and outcomes are acceptable.	Patient-level outcomes, quality of life, mortality. Surrogate outcomes are usually not appropriate unless valid and widely accepted
Bio-markers	Sample collections. Biomarker measurements where these are integral to treatment allocation.	Sample collection only funded.

Download a pdf of this page (Characteristics of Cancer Research UK and HTA programmes)

PLEASE CONTACT US HERE

printer friendly version

NETSCC is part of the Wessex Institute at the University of Southampton

Disclaimer • FOI • Privacy • Copyright • Sitemap • Contact • Complaints • Accessibility